Status:
TERMINATED
Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease
Lead Sponsor:
University of Toledo Health Science Campus
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Vascular Disease
Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Evaluate effectiveness of Carvedilol CR on Micro T-Wave Alternans in high risk hypertensives
Detailed Description
The effect of Carvedilol CR on Micro T-Wave Alternans will be assessed in 30 hypertensives with stage 4 or 5 chronic kidney disease utilizing a cross-over design and contrasting no treatment against a...
Eligibility Criteria
Inclusion
- Adults age 18 and older
- Chronic kidney disease
- Must be able to do stress test
Exclusion
- Must not be mentally disabled
- Unable to provide informed consent
- Unable or unwilling to comply with study protocol or procedures
- Pregnancy or unknown pregnancy status in female of childbearing potential
- Participation in any drug trial during the study period
- Prior enrollment in this study
- Active liver disease
- Currently on β-blocker medication at the time of enrollment
- Known history of asthma exacerbation with β-blocker therapy
- Second or third degree AV nodal block or bradycardia with resting heart rate \<50 bpm
- Prior allograft organ transplantation
- Planned allograft transplantation reasonably foreseen within the active treatment period
- Electrocardiographic left or right bundle branch block
- Permanent implanted pacemaker
- Atrial fibrillation
- Ongoing treatment with any of the following medications: sotalol (Betapace), azimilide (Stedicor), quinidine (Quinidex), disopyramide (Norpace), dofetilide (Tikosyn), ibutilide (Corvert), procainamide (Procanbid), bepridil (Vascor), amiodarone (Cordarone), clarithromycin (Biaxin), erythromycin (Eryc), halofantrine (Halfan), pentamidine (Pentam), sparfloxacin (Zagam), domperidone (Motilium), droperidol (Inapsine), chlorpromazine (Thorazine), haloperidol (Haldol), mesoridazine (Serentil), thioridazine (Mellaril), pimozide (Orap), arsenic trioxide (Trisenox), cisapride (Propulsid), lidoflazine (Clinium), and methadone (Dolophine)
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00638222
Start Date
May 1 2008
End Date
December 1 2010
Last Update
November 13 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Toledo, Health Science Campus
Toledo, Ohio, United States, 43606
2
Site Rhode Island Hospital
Providence, Rhode Island, United States, 02903